{"id":450602,"date":"2021-03-04T08:03:42","date_gmt":"2021-03-04T13:03:42","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=450602"},"modified":"2021-03-04T08:03:42","modified_gmt":"2021-03-04T13:03:42","slug":"x4-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-corporate-update\/","title":{"rendered":"X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update"},"content":{"rendered":"
\n

\n
\n 2021 expected to be a year of key value-driving catalysts as company advances multiple\u00a0<\/em>
\n <\/strong>
\n
\n clinical programs with lead candidate mavorixafor<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Company anticipates completing full enrollment in WHIM Phase 3 trial in 2021 and presenting clinical data from the ongoing Phase 1b Waldenstr\u00f6m\u2019s trial throughout the year <\/em>
\n <\/strong>\n <\/p>\n

\n
\n Conference call today at 8:30 a.m. ET<\/em>
\n <\/strong>\n <\/p>\n

BOSTON, March 04, 2021 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc.<\/a> (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today reported financial results for the fourth quarter and full year ended December 31, 2020. The company also provided an update on its lead product candidate, mavorixafor, a novel small molecule currently being evaluated in a Phase 3 clinical trial (4WHIM<\/a>) for patients with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome and in two Phase 1b trials for patients with Waldenstr\u00f6m\u2019s macroglobulinemia (Waldenstr\u00f6m\u2019s) and Severe Congenital Neutropenia (SCN), respectively.<\/p>\n

\u201cAs many companies did, we encountered a number of unexpected challenges in 2020, most notably the COVID-19 pandemic. However, I could not be prouder of our accomplishments, as we remained steadfast in our commitment to advance our lead candidate, mavorixafor, in a number of rare disease indications,\u201d said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. \u201cWe believe that we have much to look forward to this year, as we have overcome these obstacles, have made significant progress in advancing our clinical and research programs, and assembled an exceptional team to execute on our 2021 goals and beyond.<\/p>\n

\u201cOn the clinical front, we continue to expect top-line data from our Phase 3 WHIM trial in 2022 and, as our Phase 1b Waldenstr\u00f6m\u2019s trial is progressing well, we continue to expect initial data from that study in the first half of 2021, with a more fulsome dataset expected towards the end of 2021. We also anticipate initial data from our SCN Phase 1b trial in 2021.\u201d<\/p>\n

\n
\n Recent Highlights<\/u>
\n <\/strong>\n <\/p>\n